Episode Summary
In this week’s episode, John reviews CVS’ move to expand its HealthHub stores to 1,500 by the end of 2021. HealthHub stores have expanded space for health-related products and larger health clinics with a lab for blood testing and screening. They also have a general wellness room used for yoga classes and educational events.
Episode Notes
In this week’s episode, John reviews CVS’ move to expand its HealthHub stores to 1,500 by the end of 2021. HealthHub stores have expanded space for health-related products and larger health clinics with a lab for blood testing and screening. They also have a general wellness room used for yoga classes and educational events.
We also have our first subscriber feedback, which addresses John’s editorial from last week on Novartis’ new gene therapy priced at $2.1 million.
Briefs include:
- Supreme Court ruling on CMS payments to disproportionate-share hospitals.
- Partners canceling its agreement to acquire Care New England.
- Bon Secours Mercy Health selling its majority share in Ensemble Health.
- Connecticut’s withdrawal of a bill to offer a public health insurance option.
About Darwin Research Group
Darwin Research Group Inc. provides advanced market intelligence and in-depth customer insights to health care executives, with a strategic focus on health care delivery systems and the global shift toward value-based care. Darwin’s client list includes forward-thinking biopharmaceutical and medical device companies, as well as health care providers, private equity, and venture capital firms. The company was founded in 2010 as Darwin Advisory Partners, LLC and is headquartered in Scottsdale, Ariz. with a satellite office in Princeton, N.J.
CONNECT WITH US:
🌐 Follow Health Care Rounds on LinkedIn
🌐 Follow Darwin Research Group on LinkedIn
📺 Watch Health Care Rounds on YouTube
⚙️ Health Care Rounds is produced by Grippi Media
Recommended Next
Darwin's Our Take: Feature: A rare FDA refusal, CDC grant cuts, and proposed ACA exchange changes

Darwin's Our Take: Lilly’s, Novo Nordisk’s share prices roller-coaster following earnings reports

Darwin's Our Take: Botox, Trulicity, Xolair among drugs selected for next round of Medicare price negotiations

Subscribe to Our Take
Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.







